Trials / Completed
CompletedNCT00265655
Satraplatin for Patients With Metastatic Breast Cancer (MBC)
Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Agennix · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.
Detailed description
This is a Phase II open label, nonrandomized study for patients with metastatic breast cancer. WHAT IS SATRAPLATIN: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Satraplatin | Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days. |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2008-01-01
- Completion
- 2008-02-01
- First posted
- 2005-12-15
- Last updated
- 2012-03-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00265655. Inclusion in this directory is not an endorsement.